Ziprasidone elimination relies heavily on aldehyde oxidase, therefore it is possible that NAFLD patients would exhibit reduced clearance of ziprasidone due to less AOX1 expression. The gene discussed is AOX1; the disease is metabolic dysfunction-associated steatotic liver disease.